All In Biotech

Drug Trial Radar · NCT01355484

Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy

Last checked: Nov 19, 2026Latest source record: Mar 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 321 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

321

Actual

Start

Jul 2011

Primary completion

May 2013

Study completion Jun 2014

Sponsor

Lead sponsor
GTxIndustry
Sponsor type
Industry
First posted
May 18, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if the investigational drug GTx-024 can help subjects with non-small cell lung cancer increase physical function and maintain or gain muscle, also called "lean body mass".

Conditions

  • Muscle Wasting
  • Non Small Cell Lung Cancer

Interventions

  • GTx-024Drug

    subjects will be randomized to receive GTx-024 for the full duration of the trial.

  • placeboDrug

    subject will receive placebo for the duration of the trial

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Physical FunctionTime frame: Day 84
  2. Lean Body MassTime frame: Day 84

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • GTx Investigative Site

    Birmingham, Alabama

  • GTx Investigative Site

    Long Beach, California

  • GTx Investigative Site

    Aventura, Florida

  • GTx Investigative Site

    Miami, Florida

  • GTx Investigative Site

    Orange City, Florida

  • GTx Investigative Site

    Tampa, Florida

  • GTx Investigative Site

    Decatur, Illinois

  • GTx Investigative Site

    Peoria, Illinois

  • GTx Investigative Site

    Skokie, Illinois

  • GTx Investigative Site

    Indianapolis, Indiana

  • GTx Investigative Site

    Ashland, Kentucky

  • GTx Investigative Site

    Concord, Massachusetts

  • GTx Investigative Site

    Saint Clair Shores, Michigan

  • GTx Investigative Site

    Tupelo, Mississippi

  • GTx Investigative Site

    Great Falls, Montana

  • GTx Investigative Site

    Rochester, New York

  • GTx Investigative Site

    Burlington, North Carolina

  • GTx Investigative Site

    Flat Rock, North Carolina

  • GTx Investigative Site

    Wilmington, North Carolina

  • GTx Investigative Site

    Winston-Salem, North Carolina

  • GTx Investigative Site

    Canfield, Ohio

  • Gabrail Cancer Center

    Canton, Ohio

  • GTx Investigative Site

    Sandusky, Ohio

  • GTx Investigative Site

    Portland, Oregon

  • GTx Investigative Site

    Lancaster, Pennsylvania

  • GTx Investigative Site

    Spartanburg, South Carolina

  • GTx Investigative Site

    Round Rock, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.